AUTHORS
Alex J. Garcia, PhD, Shilpi Chandra, PhD2, Soheila Shirinbak, Ph.D3, Mark Jelcic, Ph.D4, Brian Groff5, Spas Markov, Ph.D6, Alma Gutierrez, MS7, Angela Gentile8, Miguel Meza9, Karina Palomares, Ph.D10, Carissa Dege, Ph.D11, Bjoern Gaertner, Ph.D12, Tom Lee, Ph.D13, Karl-Johan Malmberg, MD, PhD14, Maksim Mamonkin, PhD15, Bahram Valamehr, Ph.D16, Eigen Peralta, Ph.D17, Aimee Merino, MD, PhD18, Jeffrey Miller, MD19, Martin Hosking, Dr.20
AFFILIATIONS
1 Fate Therapeutics, Inc., San Diego, California, United States
2 Fate Therapeutics, Inc., San Diego, California, United States
3 Fate Therapeutics, Inc., San Diego, California, United States
4 Fate Therapeutics, Inc., San Diego, California, United States
5 Fate Therapeutics, Inc., San Diego, California, United States
6 Fate Therapeutics, Inc., San Diego, California, United States
7 Fate Therapeutics, Inc., San Diego, California, United States
8 Fate Therapeutics, Inc., San Diego, California, United States
9 Fate Therapeutics, Inc., San Diego, California, United States
10 Fate Therapeutics, Inc., San Diego, California, United States
11 Fate Therapeutics, Inc., San Diego, California, United States
12 Fate Therapeutics, Inc., San Diego, California, United States
13 Fate Therapeutics, Inc., San Diego, California, United States
14 Oslo University Hospital, Oslo, Norway
15 Columbia University - Vagelos College of Physicians and Surgeons, New York, New York, United States
16 Fate Therapeutics, Inc., San Diego, California, United States
17 Fate Therapeutics, Inc., San Diego, California, United States
18 University of Minnesota, Minneapolis, Minnesota, United States
19 University of Minnesota, Minneapolis, Minnesota, United States
20 Fate Therapeutics, Inc., San Diego, California, United States
ABSTRACT
Introduction: CD38 is consistently expressed on multiple myeloma, non-Hodgkin lymphoma (NHL) and B-cell leukemia tumors with CD38 and CD19 co-expression universally defining NHL (DLBCL: 96.8%, Burkitt’s: 99.1%, % >2 Log2(TPM+1)) and B-ALL (97.0%) in primary patient samples, making CD38 and CD19 co-targeting an attractive and universal therapeutic strategy.
FT839 has been engineered to specifically target CD19 and CD38 for the broad and comprehensive elimination of diverse hematologic cancers. Tumor targeting by FT839 can also be flexibly extended in combination with standard-of-care (SOC) therapeutic agents, including monoclonal antibodies (mAb) or T cell engagers (TCE) to further mitigate antigen escape.
Methods: The described product candidate, FT839, is derived from a clonal induced pluripotent stem cell (iPSC) master cell bank that has been precision-engineered to consistently and uniformly express the suite of genetic edits. The iPSC master cell bank serves as the starting cell source to manufacture FT839, overcoming numerous limitations associated with patient- and donor-sourced CAR T-cell therapies. Key features of FT839 include loci-specific incorporation of two CARs that are directed against CD19 and CD38, a high-affinity non-cleavable Fc receptor (hnCD16), and a chimeric CD3ε fusion receptor (CD3FR) that can synergistically combine with approved mAb and TCE to extend and deepen its antigen targeting. In addition, the incorporation of Sword and ShieldTM engineering introduces a synthetic alloimmune defense receptor that selectively eliminates 4-1BB+ alloreactive cells, and the genetic knockout of CD58 to prevent its recognition by host immune cells. Additional engineered elements of FT839 support tumor-directed trafficking and resistance to TGFβ mediated suppression.
Results: FT839 exerted robust and durable cytotoxicity against B-cell leukemia and lymphoma, T-cell leukemia, and multiple myeloma target lines with differential expression levels of CD19 and CD38 (>95% cytotoxicity). The versatile and unique engineering profile of FT839 also supports functional combination with SOC therapeutic agents. In combination with lenalidomide or bortezomib to upregulate CD38 expression, FT839 cytolysis of multiple myeloma target lines was significantly enhanced (~2.5x vs control). Engagement of hnCD16 or CD3FR with clinically approved therapeutic mAb or TCE targeting CD20 (e.g. rituximab or epcoritamab) reinforced FT839 cytolytic activity in scenarios of antigen heterogeneity and escape (84% vs 11% cytotoxicity FT839 +/- rituximab vs CD19KOCD38KO targets). FT839 demonstrated potent control of xenograft mouse models of B-cell ALL, Burkitt’s lymphoma, and multiple myeloma as a monotherapy or in combination with anti-CD20 mAb (91-100% tumor growth inhibition). FT839 demonstrates broad applicability across hematologic malignancies along with a unique ability to synergistically combine with therapeutic biologics and disease-modifying agents.
FT839 incorporates Sword and ShieldTM engineering technology, promoting functional persistence by directly targeting and evading alloreactive host immune cells. In models of allogeneic rejection FT839 suppressed the generation and expansion of alloreactive immune cells from HLA-mismatched PBMCs (4x vs control, p<0.0005) and primed alloreactive T cells (>6x vs control, p<0.0001), thereby enhancing FT839 persistence (21x, p<0.0001 vs control). Further, FT839 maintained durable tumor control in these allogeneic settings (>18x vs control), demonstrating that Sword and ShieldTM engineering supports the sustained effector function and long-term persistence of FT839.
Conclusion: Hematologic cancers are defined by a near-complete CD19 and/or CD38 expression. With a unique combination of CARs recognizing CD19 and CD38, FT839 is specifically engineered for the broad and comprehensive treatment of these diverse hematologic cancers. In preclinical models FT839 was universally effective against B-, T-, and plasma cell malignancies. Approved disease modifying agents synergize with CD38 CAR to deepen FT839 anti-tumor activity, and therapeutic mAbs and TCEs functionally combine with FT839 to extend its targeting capacity to additional tumor antigens. Sword and ShieldTM engineering technology enables functional persistence within allogeneic environments. Clinical development for FT839 is ongoing for hematologic malignancies and autoimmune disorders.
DISCLOSURES
Alex J. Garcia, PhD: Fate Therapeutics Inc. - Current equity holder in publicly-traded company; Fate Therapeutics Inc. - Current Employment